Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03362658 · ClinicalTrials.gov registry record
Novel MRI Biomarkers for Monitoring Disease Progression in ALS
A clinical trial of Amyotrophic Lateral Sclerosis and Motor Neuron Disease, sponsored by University of Alberta.
- Recruiting
- Registry status
- 700
- Enrollment target
- 9
- Study locations
NCT03362658: Recruiting study of Amyotrophic Lateral Sclerosis and Motor Neuron Disease, sponsored by University of Alberta.
NCT03362658 is a study of Amyotrophic Lateral Sclerosis and Motor Neuron Disease that is actively recruiting participants, run by University of Alberta. The registered enrollment target is 700 participants, below the 891-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (21% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03362658, a study of Amyotrophic Lateral Sclerosis and Motor Neuron Disease, is actively recruiting participants, sponsored by University of Alberta.
- RECRUITING
- Registry status
- 700 participants
- Enrollment target
- 9
- Study locations
Study Summary
Routine MRI is normal in motor neuron diseases such as ALS. However, advanced MRI techniques can provide an objective measure of degeneration (a "biomarker") by examining brain structure, wiring, chemistry, and function. We will develop and evaluate novel MRI techniques that could improve our understanding of ALS and provide a means to diagnose it sooner and monitor its progression. Importantly, we expect these techniques to improve how new drugs are tested, which may lead to the more rapid discovery of a treatment for ALS. Each participant will have 3 MRI scans over a period of 8 months, along with neurological and cognitive evaluations. Study visits will take 2 - 3 hours. MRI is a safe technique that does not involve radiation.
Primary Outcome
This primary analysis will evaluate neuronal integrity at baseline and specified follow up periods. Patients and controls scans will be compared.
Conditions Studied
Study Locations (9)
Alberta
- University of Calgary / Heritage Medical Research Clinic - Calgary
- University of Alberta - Edmonton
Ontario
- Western University / London Health Sciences Centre - London
- University of Toronto / Sunnybrook Health Sciences Centre - Toronto
Quebec
- McGill University / Montreal Neurological Institute and Hospital - Montreal
- Laval University - Québec
Florida
- University of Miami - Miami
Utah
- University of Utah - Salt Lake City
British Columbia
- University of British Columbia / GF Strong Rehab Centre - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2016-10 |
| Est. Completion | 2025-12-31 |
What NCT03362658 shows while recruiting
NCT03362658 is an observational study that tracks outcomes without assigning an intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, below the 891-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (21% lower).
The record links to 2 conditions, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT03362658 lists 9 locations in 6 states (Alberta, Ontario, Quebec).
Frequently Asked Questions
What is clinical trial NCT03362658 about?
NCT03362658 is a clinical study titled "Novel MRI Biomarkers for Monitoring Disease Progression in ALS". Routine MRI is normal in motor neuron diseases such as ALS. However, advanced MRI techniques can provide an objective measure of degeneration (a "biomarker") by examining brain structure, wiring, chemistry, and function. We will develop and evaluate novel MRI techniques that could improve our unders...
What is the current status of trial NCT03362658?
This trial is currently recruiting. The enrollment target is 700 participants. The study started on 2016-10. Estimated completion is 2025-12-31.
What conditions does trial NCT03362658 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis, Motor Neuron Disease.
Who is sponsoring clinical trial NCT03362658?
This trial is sponsored by University of Alberta, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03362658 being conducted?
This trial has 9 study locations across Florida, Utah, Alberta, British Columbia, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03362658's enrollment target sits among peer trials
700 15th of 102 higher than 88 of 102 other Amyotrophic Lateral Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)
RECRUITING · NA
-
Assessing Perceptual Effects of Interactive Tasks
RECRUITING · NA
-
PREVENT ALL ALS Study
RECRUITING
-
Spinal Cord Associative Plasticity for ALS
RECRUITING · NA
-
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
RECRUITING · NA
-
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
- NCT02129543 · 700 participants
Immune Reconstitution in Stem Cell Transplant Recipients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia